Table 1.
Characteristics of patients included in this study
Feature | Grouping | N or value | % |
---|---|---|---|
Age | Mean | 53.9 | |
Range | 38–81 | ||
Histologic type | Invasive ductal carcinoma | 30 | 81.1 |
Others | 4 | 10.8 | |
Unknown | 3 | 8.1 | |
Histologic grade | 1 | 1 | 2.7 |
2 | 8 | 21.6 | |
3 | 20 | 54.1 | |
Unknown | 8 | 21.6 | |
TNM stage | 1 | 6 | 16.2 |
2 | 13 | 35.1 | |
3 | 9 | 24.3 | |
4 | 1 | 2.7 | |
Unknown | 8 | 21.6 | |
ER status of primary tumor | Positive | 16 | 43.2 |
Negative | 21 | 56.8 | |
PR status of primary tumor | Positive | 13 | 35.1 |
Negative | 24 | 64.9 | |
HER2 status of primary tumor | Positive | 19 | 51.4 |
Negative | 18 | 48.6 | |
Primary breast cancer subtype | HR+, HER2− | 13 | 35.1 |
HR+, HER2+ | 3 | 8.1 | |
HR−, HER2+ | 16 | 43.2 | |
HR−, HER2− | 5 | 13.5 | |
Multiplicity | Single brain metastasis | 28 | 75.7 |
Multiple metastasis | 9 | 24.3 | |
Brain metastasis location | Supratentorial | 25 | 67.6 |
Infratentorial | 8 | 21.6 | |
Both | 4 | 10.8 |
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hormone receptor